title: Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations.
abstract: This review is the synthesis of a working group on mild asthma. Mild asthma includes intermittent and persistent mild asthma according to the Global Initiative for Asthma (GINA) classification, and affects between 50% and 75% of asthmatic patients. Mild asthma is more frequent, more symptomatic, and less well controlled in children than in adults. Cohort studies from childhood to adulthood show that asthma severity usually remains stable over time. Nevertheless, mild asthma can lead to severe exacerbations, with a frequency ranging from 0.12 to 0.77 per patient-year. Severe exacerbations in mild asthma represent 30-40% of asthma exacerbations requiring emergency consultation. In mild asthma, inflammation and structural remodelling are constant, of varying intensity, but nonspecific. Therapy with inhaled corticosteroids (ICS) decreases bronchial inflammation, but has only a slight effect on structural remodelling, and, when stopped, inflammation immediately recurs. Permanent low-dose ICS therapy is the reference treatment for persistent mild asthma. Effectiveness is to be reassessed at 3 months, and if it is insufficient the patient is no longer considered mildly asthmatic, and treatment has to be stepped up. As mild asthma is the most frequent form of the disease, diagnosis and management require physicians' particular attention.
authors.affiliation: Department of Pneumology, Cochin Hospital, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Dusser
authors.forename: D
authors.initials: D
authors.lastname: Montani
authors.forename: P
authors.initials: P
authors.lastname: Chanez
authors.forename: J
authors.initials: J
authors.lastname: de Blic
authors.forename: C
authors.initials: C
authors.lastname: Delacourt
authors.forename: A
authors.initials: A
authors.lastname: Deschildre
authors.forename: P
authors.initials: P
authors.lastname: Devillier
authors.forename: A
authors.initials: A
authors.lastname: Didier
authors.forename: C
authors.initials: C
authors.lastname: Leroyer
authors.forename: C
authors.initials: C
authors.lastname: Marguet
authors.forename: Y
authors.initials: Y
authors.lastname: Martinat
authors.forename: J
authors.initials: J
authors.lastname: Piquet
authors.forename: C
authors.initials: C
authors.lastname: Raherison
authors.forename: P
authors.initials: P
authors.lastname: Serrier
authors.forename: I
authors.initials: I
authors.lastname: Tillie-Leblond
authors.forename: A-B
authors.initials: AB
authors.lastname: Tonnel
authors.forename: M
authors.initials: M
authors.lastname: Tunon de Lara
authors.forename: M T
authors.initials: MT
authors.lastname: de Lara
authors.forename: M
authors.initials: M
authors.lastname: Humbert
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000367:Age Factors; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans
chemical_list: D000305:Adrenal Cortex Hormones; D001993:Bronchodilator Agents